SVB Leerink assumed coverage on shares of LENZ Therapeutics (NASDAQ:LENZ – Free Report) in a research note issued to investors on Monday, MarketBeat Ratings reports. The brokerage issued an outperform rating and a $32.00 price objective on the stock.
LENZ has been the subject of several other reports. William Blair started coverage on shares of LENZ Therapeutics in a research note on Monday. They issued an outperform rating for the company. Citigroup assumed coverage on LENZ Therapeutics in a research note on Wednesday, April 10th. They issued a buy rating and a $34.00 target price for the company. Finally, Piper Sandler assumed coverage on LENZ Therapeutics in a research note on Wednesday, March 27th. They issued an overweight rating and a $28.00 price target on the stock. Five analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of Buy and a consensus price target of $31.33.
View Our Latest Analysis on LENZ Therapeutics
LENZ Therapeutics Price Performance
Insider Activity
In other LENZ Therapeutics news, Director Ra Capital Management, L.P. bought 998,009 shares of the business’s stock in a transaction that occurred on Thursday, March 21st. The shares were bought at an average cost of $15.03 per share, with a total value of $15,000,075.27. Following the completion of the purchase, the director now directly owns 3,319,339 shares of the company’s stock, valued at $49,889,665.17. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 38.40% of the company’s stock.
About LENZ Therapeutics
LENZ Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing aceclidine-based eye drop to enhance vision in patients diagnosed with presbyopia. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Featured Stories
- Five stocks we like better than LENZ Therapeutics
- Technology Stocks Explained: Here’s What to Know About Tech
- United Airlines Soars on Earnings Beat
- How to buy stock: A step-by-step guide for beginners
- J.B. Hunt Hits the Skids: Lower Prices to Come
- What is the S&P 500 and How It is Distinct from Other Indexes
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for LENZ Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LENZ Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.